Editor's note

This ExpertREACT article was originally published on 12 January 2009. Policy data and programme statuses described reflect the state of knowledge at that date.

Three pandemics in the twentieth century: a lesson not forgotten

Influenza pandemics - caused by new subtypes of influenza A spreading in populations with little or no pre-existing immunity - represent one of the most serious threats to global human health. The twentieth century witnessed three significant pandemics: 1918 (A/H1N1 Spanish flu), 1957 (A/H2N2) and 1968 (A/H3N2). Each was associated with high clinical attack rates of 25-35% and elevated case fatality rates, with the 1918 pandemic alone estimated to have killed 50-100 million people. Even a "mild" pandemic similar to those of 1957 and 1968 could kill millions in today's more populous and connected world.

President Bush's November 2005 National Strategy for Pandemic Influenza mobilised $7.1bn in HHS budget authority, of which approximately $4bn was allocated to vaccine-related activities: production capacity expansion, stockpile building and investment in cell-based expression systems to move beyond egg-dependent manufacturing. As of December 2008, 67 countries had confirmed H5N1 in animals - a dramatic increase from 11 countries in 2004 - reinforcing the need for ongoing preparedness. HHS Secretary Levitt's January 2009 update confirmed substantial progress: antigen stockpile expansion, multiple cell-based vaccine manufacture clinical trial completions, and advances in adjuvant-based dose-sparing approaches.

Countries with H5N1 in animals (Dec 2008)
67
Up from 11 countries in 2004; H5N1 avian influenza continued to spread geographically despite no confirmed sustained human-to-human transmission

Cell-based capacity and the priming debate

A central theme of the US pandemic plan was accelerating the transition from egg-based to cell-based influenza vaccine manufacturing, which would substantially reduce lead times for pandemic vaccine production. Multiple cell-based clinical trials had been completed by early 2009, though none of the cell-derived vaccines had yet achieved US licensure for seasonal use - a prerequisite for any pandemic deployment. The update also addressed the ongoing expert debate around pre-emptive priming strategies - providing populations with H5N1 antigen in advance to prime immune memory - as a complement to reactive vaccine strategies. VacZine Analytics viewed the HHS update as a positive signal that vaccine preparedness infrastructure was meaningfully advancing, even if critical technology transitions remained incomplete.